Contrary to initial concerns, long-term safety data for thrombopoietin receptor agonists has allayed fears of malignant transformation and irreversible bone marrow fibrosis. The increased reticulin fibrosis observed is reversible upon drug discontinuation, offering significant reassurance for long-term prescribing.

The target platelet count for ITP patients should be tailored to their lifestyle, bleeding history, and quality of life goals. A normal platelet count is not necessary, and different thresholds are appropriate for different patients (e.g., someone planning a ski trip versus a sedentary individual).

Historical data on high splenectomy success rates in ITP is outdated. For modern patients who have already failed multiple lines of therapy (e.g., corticosteroids and a TPORA), the likelihood of a curative response from splenectomy falls to around 40-45%, making it a less appealing option.

The treatment paradigm for ITP is shifting towards early combination therapy. Recent clinical trials are investigating augmented first- and second-line regimens, such as combining dexamethasone with rituximab or romiplostim, to achieve more durable, treatment-free responses than monotherapy.

Unlike neutropenia, which has established management with G-CSF, CIT is often undertreated. This leads to chemotherapy dose reductions that can worsen patient outcomes. Newer TPO receptor agonists are effective, but the problem itself remains an underappreciated gap in oncology practice.

Concerns about bone marrow fibrosis with TPO receptor agonists have been resolved. The effect is a reversible increase in reticulin fibrosis, not the permanent collagen fibrosis seen in myelofibrosis. It resolves upon stopping the drug, so routine bone marrow biopsies for monitoring are unnecessary.

Patients with ITP who fail or are intolerant to one TPO receptor agonist (e.g., eltrombopag) should not be considered a class failure. Switching to another TPO agent is a viable strategy that can induce a response in nearly half of these cases, particularly for intolerance.

To minimize steroid toxicity, a thrombopoietin receptor agonist (TPORA) should be the immediate second-line therapy for ITP patients who fail their initial course of corticosteroids. There is no need to trial multiple other therapies before considering a TPORA.

Eltrombopag is a potent iron chelator that can cause or worsen iron deficiency. In ITP patients with existing iron deficiency, alternative TPO receptor agonists like avatrombopag or romiplostim, which do not chelate iron, should be used instead.